<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03074019</url>
  </required_header>
  <id_info>
    <org_study_id>PRENRPD-150002-RPD01</org_study_id>
    <nct_id>NCT03074019</nct_id>
  </id_info>
  <brief_title>Pilot Study on the Effect of a XOS95 on the Human Gut Microbiome</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group, Pilot Study on the Effect of a Novel Prebiotic, XOS95, on the Human Gut Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prenexus Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nutrasource Pharmaceutical and Nutraceutical Services, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prenexus Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to assess the efficacy of a novel prebiotic, XOS95, at&#xD;
      two different dosages, in comparison to a placebo by assessing shifts in microbial&#xD;
      populations after 8 weeks of supplementation, assessed as changes in abundance of microbial&#xD;
      populations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">September 28, 2017</completion_date>
  <primary_completion_date type="Actual">August 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, 3-arm, parallel, dose ranging study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of XOS95 on abundance of microbial populations by 16S RNA sequencing of feces</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of XOS95 on short chain fatty acid production measured in the feces</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of XOS95 on gastrointestinal bacterial counts in the feces</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of XOS95 on fasting blood glucose</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of XOS 95 on post-prandial glucose response</measure>
    <time_frame>8 weeks</time_frame>
    <description>2 hour post-prandial response to a 75g oral glucose challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of XOS 95 on lipid profile parameters</measure>
    <time_frame>4 and 8 weeks</time_frame>
    <description>Effect of XOS 95 on lipid profile parameters (Total cholesterol, LDL-C, HDL-C and triglycerides)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of XOS 95 on C-reactive protein</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of XOS on abdominal discomfort assessed by daily questionnaire</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of XOS on general well-being assessed by daily questionnaire</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of XOS on total Gastrointestinal Quality of Life Index (GIQLI) scores</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of subjects with a treatment emergent adverse effect</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Xylooligosaccharide (Low Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5g XOS95 + 1.5g Maltodextrin powder, taken orally mixed in water, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xylooligosaccharide (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3g XOS95 powder, taken orally mixed in water, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3g maltodextrin powder, taken orally mixed in water, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Xylooligosaccacharide</intervention_name>
    <description>XOS95 powder</description>
    <arm_group_label>Xylooligosaccharide (High Dose)</arm_group_label>
    <arm_group_label>Xylooligosaccharide (Low Dose)</arm_group_label>
    <other_name>XOS95</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Maltodextrin powder</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adults aged 18 - 60 (inclusive)&#xD;
&#xD;
          -  Healthy as determined from medical history&#xD;
&#xD;
          -  Non-smoker, or ex-smoker ≥6 months&#xD;
&#xD;
          -  Body mass index 18.5 - 27.5kg/m2 (inclusive)&#xD;
&#xD;
          -  Female subjects of childbearing potential [i.e. not surgically sterilized or&#xD;
             post-menopausal (greater than one year since last menses)] must have negative urine&#xD;
             pregnancy test and must be using an effective birth control method , defined as:&#xD;
&#xD;
               -  Continuous use of oral or long acting injected contraceptive for at least 2&#xD;
                  months prior to study entry , or&#xD;
&#xD;
               -  Use of an intra-uterine device or implantable contraceptive, or&#xD;
&#xD;
               -  Use of double barrier methods of birth control, or&#xD;
&#xD;
               -  Abstinence from heterosexual intercourse&#xD;
&#xD;
          -  Willing to avoid alcohol consumption for 24 h prior to every clinic visit&#xD;
&#xD;
          -  Willing to maintain their regimens of medications and supplements known to alter GI&#xD;
             function (including, but not limited to, iron supplements, calcium, and&#xD;
             anti-depressants)&#xD;
&#xD;
          -  Willing to maintain a stable body weight, activity level and dietary pattern except&#xD;
             for use of the study products, as directed&#xD;
&#xD;
          -  Willing and able to provide informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation, or subject unwilling to take appropriate contraceptives for&#xD;
             the duration of the study&#xD;
&#xD;
          -  Use of prescription non-steroidal anti-inflammatory drugs (or daily use of over the&#xD;
             counter non-steroidal anti-inflammatory drugs &gt;1month), steroids, corticosteroids, or&#xD;
             any other prescription anti-inflammatory drugs within 3 months prior to visit 1&#xD;
&#xD;
          -  Individuals taking any over the counter or prescription medications, including natural&#xD;
             health products, that may alter lipid profiles including, but not limited to fish oil&#xD;
             (omega-3 fatty acids), statins, fibrates, bile acid exchanger resin, phytosterols,&#xD;
             niacin or its analogues, carnitine, polyglucosamines (Chitosan) or other lipid-binding&#xD;
             ingredients within the 3 months prior to visit 1&#xD;
&#xD;
          -  Individuals taking any over the counter or prescription medications, including natural&#xD;
             health products that may alter blood glucose (e.g. biguanides (Metformin),&#xD;
             Alpha-lipoic Acid (ALA), Gymnema sylvestre) or insulin modulating medications (e.g.&#xD;
             sulfonylureas, meglitinides, D-phenylalanine derivatives, thiazolidinediones, DPP-4&#xD;
             inhibitors, alpha-glucosidase inhibitors, bile acid sequestrants within 3 months prior&#xD;
             to visit 1&#xD;
&#xD;
          -  Use of proton pump inhibitors or medications which inhibit peristaltic movement (e.g.&#xD;
             opioids, loperamide)&#xD;
&#xD;
          -  Unstable use (i.e. initiation or change in dose) of antihypertensive medications or&#xD;
             thyroid hormone replacement medications within 3 months prior to visit 1&#xD;
&#xD;
          -  Use of any weight-loss programs or weight-loss medications (prescription or over-the&#xD;
             counter) including, but not limited to, lipase inhibitors, within 3 months prior to&#xD;
             visit&#xD;
&#xD;
          -  Use of over the counter or prescription laxatives or stool softeners within 1 month&#xD;
             prior to baseline (V2)&#xD;
&#xD;
          -  Use of antibiotics (other than topical) within 2 months prior to baseline (V2)&#xD;
&#xD;
          -  Use of prebiotic or fiber supplements (e.g. fructans and galacto-oligosaccharides&#xD;
             (FOS, GOS), psyllium, fiber, inulin, glucomannan, acacia fiber/gum) or probiotic&#xD;
             supplements (i.e. live microorganisms) within 4 weeks of baseline (V2)&#xD;
&#xD;
          -  Consumption of specific functional prebiotic- or probiotic-rich foods within 4 weeks&#xD;
             of baseline (V2) (Appendix 3)&#xD;
&#xD;
          -  History of blood clotting disorders or use of coagulation-inhibiting drugs (e.g.&#xD;
             warfarin)&#xD;
&#xD;
          -  Individuals with achlorhydria&#xD;
&#xD;
          -  Presence of major diseases such as diabetes, gastrointestinal, endocrine,&#xD;
             cardiovascular, pancreatic, renal, or liver disease&#xD;
&#xD;
          -  Chronic diarrhea or constipation, irritable bowel syndrome, celiac disease,&#xD;
             gluten-sensitive enteropathy, or inflammatory bowel disease&#xD;
&#xD;
          -  Abdominal or gastrointestinal surgery within the previous 12 months or planned&#xD;
             abdominal or gastrointestinal surgery or procedures such as colonoscopy in the next 4&#xD;
             months&#xD;
&#xD;
          -  Recent gastrointestinal food-borne illness (within 1 month prior to visit 1)&#xD;
&#xD;
          -  History of neurological disease (e.g. Parkinson's disease, stroke, traumatic brain&#xD;
             injury, etc.)&#xD;
&#xD;
          -  History of cancer (excluding non-melanoma skin cancer and basal cell carcinoma) in the&#xD;
             past 5 years&#xD;
&#xD;
          -  Uncontrolled hypertension defined as a seated resting systolic blood pressure ≥140&#xD;
             mmHg and/or diastolic blood pressure ≥90 mmHg&#xD;
&#xD;
          -  Abnormal laboratory test results of clinical significance, including, but not limited&#xD;
             to ALT or AST ≥1.5X the upper limit of normal at screening (visit 1)&#xD;
&#xD;
          -  Presence or history (past 6 months) of alcohol or drug abuse; alcohol use of &gt;2&#xD;
             standard alcoholic drinks per day&#xD;
&#xD;
          -  Extreme dietary habits (e.g. vegan or very low carbohydrate diets, gluten-free diet,&#xD;
             low FODMAP diet)&#xD;
&#xD;
          -  Subject has a known allergy or intolerance to the test products or placebo&#xD;
&#xD;
          -  Subject is unwilling or unable to abide by the requirements of the protocol&#xD;
&#xD;
          -  Any condition that would interfere with the subject's ability to comply with study&#xD;
             instructions, might confound the interpretation of the study, or put the subject at&#xD;
             risk&#xD;
&#xD;
          -  Subject has taken an investigational health product or has participated in a research&#xD;
             study within 30 days prior to first study visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nutrasource Diagnostics Inc.</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1G 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

